




RealRate

PHARMACEUTICAL 2024

Edesa Biotech Inc
Rank 122 of 309



Edesa Biotech



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Edesa Biotech Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Edesa Biotech Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 112% points. The greatest weakness of Edesa Biotech Inc is the variable Other Net Income, reducing the Economic Capital Ratio by 106% points.

The company's Economic Capital Ratio, given in the ranking table, is 253%, being 40% points above the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	6,437
Cost of Goods Sold	0
Intangible Assets	2,180
Liabilities, Current	1,822
Liabilities, Non-Current	20
Other Assets	265
Other Compr. Net Income	-1.0
Other Expenses	0.80
Other Liabilities	0
Other Net Income	-8,374
Other Revenues	0
Property and Equipment	8.7
Research and Development	0
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	8,890
Liabilities	1,842
Expenses	0.80
Revenues	0
Stockholders Equity	7,049
Net Income	-8,374
Comprehensive Net Income	-8,375
BaseVar	9,554
ECR before LimitedLiability	130%
Economic Capital Ratio	253%